Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose

Next Previous
Trial Profile

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostemsavir (Primary) ; Atazanavir; Raltegravir; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; ViiV Healthcare

Most Recent Events

  • 08 Oct 2020 Results assessing Fostemsavir exposure-response relationships from Phase II and Phase III studies presented at the 15th International Congress on Drug Therapy and HIV Infection
  • 11 Mar 2020 Results assessing Fostemsavir Exposure-Response Relationships in Treatment-Experienced Hiv Patients from NCT01384734 and NCT02362503,presented at the 27th Conference on Retroviruses and Opportunistic Infections
  • 07 Mar 2019 Efficacy results through Week 192, presented at the 26th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top